Naoe Y - Search Results

1

Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors.

Terasaka T, Okumura H, Tsuji K, Kato T, Nakanishi I, Kinoshita T, Kato Y, Kuno M, Seki N, Naoe Y, Inoue T, Tanaka K, Nakamura K. Terasaka T, et al. Among authors: naoe y. J Med Chem. 2004 May 20;47(11):2728-31. doi: 10.1021/jm0499559. J Med Chem. 2004. PMID: 15139750

2

Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo.

Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S. Sasakawa Y, et al. Among authors: naoe y. Biochem Pharmacol. 2002 Oct 1;64(7):1079-90. doi: 10.1016/s0006-2952(02)01261-3. Biochem Pharmacol. 2002. PMID: 12234611

3

Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors.

Sasakawa Y, Naoe Y, Noto T, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S. Sasakawa Y, et al. Among authors: naoe y. Biochem Pharmacol. 2003 Sep 15;66(6):897-906. doi: 10.1016/s0006-2952(03)00411-8. Biochem Pharmacol. 2003. PMID: 12963476

4

Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo.

Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S. Sasakawa Y, et al. Among authors: naoe y. Cancer Lett. 2003 Jun 10;195(2):161-8. doi: 10.1016/s0304-3835(03)00184-8. Cancer Lett. 2003. PMID: 12767524

5

Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor.

Sasakawa Y, Naoe Y, Sogo N, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S. Sasakawa Y, et al. Among authors: naoe y. Biochem Pharmacol. 2005 Feb 15;69(4):603-16. doi: 10.1016/j.bcp.2004.11.008. Epub 2004 Dec 23. Biochem Pharmacol. 2005. PMID: 15670579

6

Cytotoxic mechanisms of FK317, a new class of bioreductive agent with potent antitumor activity.

Naoe Y, Inami M, Kawamura I, Nishigaki F, Tsujimoto S, Matsumoto S, Manda T, Shimomura K. Naoe Y, et al. Jpn J Cancer Res. 1998 Jun;89(6):666-72. doi: 10.1111/j.1349-7006.1998.tb03269.x. Jpn J Cancer Res. 1998. PMID: 9703365 Free PMC article.

7

FR177391, a new anti-hyperlipidemic agent from Serratia. II. Pharmacological activity of FR177391.

Inami M, Kawamura I, Tsujimoto S, Yasuno T, Lacey E, Hirosumi J, Takakura S, Nishigaki F, Naoe Y, Manda T, Mutoh S. Inami M, et al. Among authors: naoe y. J Antibiot (Tokyo). 2005 Oct;58(10):640-7. doi: 10.1038/ja.2005.88. J Antibiot (Tokyo). 2005. PMID: 16392680

8

FK317: a novel substituted dihydrobenzoxazine with potent antitumor activity which does not induce vascular leak syndrome.

Naoe Y, Inami M, Matsumoto S, Nishigaki F, Tsujimoto S, Kawamura I, Miyayasu K, Manda T, Shimomura K. Naoe Y, et al. Cancer Chemother Pharmacol. 1998;42(1):31-6. doi: 10.1007/s002800050781. Cancer Chemother Pharmacol. 1998. PMID: 9619755

9

Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome induced by colon26 adenocarcinoma in mice.

Kawamura I, Lacey E, Yamamoto N, Sakai F, Takeshita S, Inami M, Nishigaki F, Naoe Y, Tsujimoto S, Manda T, Shimomura K, Goto T. Kawamura I, et al. Among authors: naoe y. Anticancer Res. 1999 Sep-Oct;19(5B):4105-11. Anticancer Res. 1999. PMID: 10628361

10

Effects of a novel pyridylsulphonyl thiazole derivative, FR115092, on autoimmune and mitomycin C-induced thrombocytopenia in mice.

Nishigaki F, Tsujimoto S, Inami M, Matsumoto S, Naoe Y, Kawamura I, Manda T, Shimomura K. Nishigaki F, et al. Among authors: naoe y. J Pharm Pharmacol. 1999 Jul;51(7):857-65. doi: 10.1211/0022357991773078. J Pharm Pharmacol. 1999. PMID: 10467963

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88 results

Search Page

Filters